NCT05496595 is a Phase 1 clinical trial of DCBY02 in Advanced or Metastatic Solid Tumors, sponsored by DynamiCure Biotechnology.

Who is sponsoring NCT05496595?

NCT05496595 is sponsored by DynamiCure Biotechnology.

What drugs are being tested in NCT05496595?

Interventions in NCT05496595: DCBY02.

What condition does NCT05496595 study?

NCT05496595 studies Advanced or Metastatic Solid Tumors.

Is NCT05496595 still recruiting?

NCT05496595 is currently terminated. Last updated 6 March 2024.

Last reviewed 2024-03-06 · How we verify

NCT05496595

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors

Terminated Phase 1 Last updated 6 March 2024

What this trial tests

Phase 1 trial testing DCBY02 in Advanced or Metastatic Solid Tumors in 5 participants. Terminated before completion.

Timeline

26 October 2022

Primary endpoint
5 February 2024

5 February 2024

Quick facts

Lead sponsor	DynamiCure Biotechnology
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	5
Start date	26 October 2022
Primary completion	5 February 2024
Estimated completion	5 February 2024
Sites	3 locations across United States

Drugs / interventions tested

DCBY02 — full drug profile →

Conditions studied

Advanced or Metastatic Solid Tumors — all drugs for Advanced or Metastatic Solid Tumors →

Sponsor

DynamiCure Biotechnology — full company profile →

Who can join

18 and older, any sex, with Advanced or Metastatic Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study DCBY02-101 is a multicenter, open-label, Phase 1 study to assess the effects of anti-CD93 mAb (DCBY02) as a monotherapy in patients with advanced or metastatic solid tumors.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Matrix Remodeling Associated Genes (MXRAs): structural diversity, functional significance, and therapeutic potential in tumor microenvironments.
Zeng C, Lv X, Wang F, Huang Y, et al · · 2025 · PMID 40394417 · DOI 10.1007/s12672-025-02728-4

Verify or expand the search:

Other recruiting trials for Advanced or Metastatic Solid Tumors

Currently open trials in the same condition.

NCT07510828 — PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07205718 — A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07260305 — A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolima · Phase 1 · recruiting
NCT06548217 — A Phase I Study of ONO-4538HSC in Subjects With Advanced or Metastatic Solid Tumors · Phase 1 · active not recruiting
NCT05957081 — Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05496595 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by DynamiCure Biotechnology
Last refreshed: 6 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05496595.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing